Interleukin polymorphisms and protein levels associated with lung cancer susceptibility and phenotypes

ABSTRACT

Background

We conducted a comprehensive analysis to explore whether multiple interleukin (IL), IL-1β, IL-4, IL-6, IL-8 and IL-10, polymorphisms and IL proteins (IL-6, IL-10) relate to lung cancer (LC) susceptibility or clinical characteristics.

Methods

We performed the standard meta-analysis procedures according to PRISMA. The odds ratio (OR) and mean difference (MD) were used for analysis.

Results

We investigated 11 variants from 43 articles, and found that IL-1β rs16944 (p = 0.04) and IL-10 rs1800872 (p = 0.003) decreased while IL-10 rs1800896 (p = 0.007) increased LC risks. We also found that IL-1β rs1143627 decreased NSCLC risks (p = 0.03). The heterozygotes and homozygotes contributed differently. In addition, another 15 articles were involved to explore the relationship between IL proteins and LC. We found that LC patients accounted for higher serum IL-6 of 16.60 pg/mL (p < 0.00001) and higher serum IL-10 of 3.47 pg/mL (p = 0.02) than that of controls. Furthermore, IIIA-Ⅳ LC patients tended to have higher proportion of positive IL-6 staining in lung tumor tissue in contrast with IA-IIB patients by TNM stage (p = 0.0002).

Conclusions

Four variants from IL-1β and IL-10, and serum IL-6 and IL-10 levels are associated with LC risks.

KEYWORDS:

• IL-1β
• IL-6
• IL-10
• polymorphism
• lung cancer

Author’s Contribution

Study design: MH.Y., and Y.Z., data collection: KY.D., MH.Y., LS.L. and Y.Z., data analysis: KY.D., MH.Y., LS.L. and Y.Z., writing: KY.D., MH.Y., LS.L. and Y.Z., funding: MH.Y., and Y.Z., administration: MH.Y., and Y.Z.

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Key issues

• IL-1β rs16944 and IL-10 rs1800872 could decrease while IL-10 rs1800896 could increase LC risk, and IL-1β rs1143627 could decrease NSCLC risk.

• LC patients have higher serum expression of IL-6 and IL-10 than healthy controls.

• Lung tumor tissue has higher risk of IL-6 infiltration in advanced (IIIA-Ⅳ) LC patients than early (IA-IIB) LC patients.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplementary material

Supplemental data for this article can be accessed here.

Additional information

Funding

This research was supported by the Hunan Provincial Natural Science Foundation of China (No. 2020JJ5951), the Changsha Municipal Natural Science Foundation(No. kq2014123), the Scientific Research Project of Hunan Provincial Health Commission (No. 202103021406), the Youth Science Foundation of Xiangya Hospital (No. 2019Q17), the Degree & Postgraduate Education Reform Project of Central South University (No. 2020JGB125, No. 2021YJSKSA10) and the Undergraduate Education Reform Project of Central South University (No. 2020jy146, No.2020kcsz032).